Company intelligence / Profile preview
Sementis Ltd
Adelaide, South Australia, Australiasementis.com.au ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Extensive pre-clinical studies have shown that vaccines using the SCV platform are safe and efficacious after a single vaccination, eliciting potent T and B-cell immunity, and long-lasting protective immune responses. The company is currently focused on final GLP toxicology and immunogenicity studies in preparation for first-in-human Phase I clinical trials.[2]
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Viral vector vaccines
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
University of South Australia
Beyond the preview
Go deeper on Sementis Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sementis Ltd.